title: Immunomodulatory effects of interferon-gamma in patients with metastatic malignant melanoma.
abstract: Interferon-gamma (IFN-gamma) is a potent monocyte/macrophage activating agent that in animal models exhibits a bell-shaped dose-response curve of immunomodulatory activity and antitumor efficacy. Previous clinical trials of IFN-gamma conducted at the maximal tolerated dose (MTD) have been associated with low response rates that may have been due to failure to treat at an optimal immunomodulatory dose (OID). The objective of this study was to test the hypothesis that optimal immunomodulatory activity of IFN-gamma in patients with metastatic melanoma would be obtained at a dose below the MTD. Groups of five patients each were given daily subcutaneous injections of IFN-gamma at doses of 0.01, 0.1, or 0.25 mg/m2. In vivo immunomodulation was assessed by serial measurement of serum neopterin and by flow cytometry. IFN-gamma doses of 0.1 or 0.25 mg/m2 induced significantly greater immunomodulation of monocyte-associated immune parameters than 0.01 mg/m2. Changes in immunologic parameters included marked elevation of serum neopterin levels, significant increases in monocyte expression of CD64, beta 2-microglobulin, and HLA-ABC, and decreased monocyte expression of CD14. The most dramatic decreases in CD14 expression were observed on monocytes obtained from patients treated at 0.25 mg/m2. The 0.25-mg/m2 dose group had significantly lower white blood cell counts on day 14. No bell-shaped curve of immunologic response was observed over the dosage range tested. Based on the similarity of the immunologic effects at 0.1 and 0.25 mg/m2, treatment at the MTD of IFN-gamma (0.25 mg/m2) represents treatment at the OID for patients with metastatic malignant melanoma.
authors: Clinical Immunology Services, Program Resources, Inc./DynCorp., NCI-FCRDC, Frederick, MD 21702.
authors: W C
authors: WC
authors: Kopp
authors: J W
authors: JW
authors: Smith
authors: C H
authors: CH
authors: Ewel
authors: W G
authors: WG
authors: Alvord
authors: C
authors: C
authors: Main
authors: P M
authors: PM
authors: Guyre
authors: R G
authors: RG
authors: Steis
authors: D L
authors: DL
authors: Longo
authors: W J
authors: WJ
authors: Urba
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D000368:Aged; D001708:Biopterins / Q000031:analogs & derivatives / Q000097:blood; D005260:Female; D006681:HLA-D Antigens / Q000097:blood; D006403:Hematologic Tests; D015395:Histocompatibility Antigens Class I / Q000097:blood; D006801:Humans; D007371:Interferon-gamma / Q000008:administration & dosage* / Q000009:adverse effects; D008285:Major Histocompatibility Complex / Q000276:immunology; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000276:immunology / Q000556:secondary; D008875:Middle Aged; D015166:Monitoring, Immunologic / Q000379:methods; D019798:Neopterin; D011994:Recombinant Proteins
chemical_list: D000276:Adjuvants, Immunologic; D006681:HLA-D Antigens; D015395:Histocompatibility Antigens Class I; D011994:Recombinant Proteins; D001708:Biopterins; D019798:Neopterin; D007371:Interferon-gamma